RecruitingNot ApplicableNCT06824818

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients


Sponsor

University of Chicago

Enrollment

155 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.


Eligibility

Sex: MALEMin Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether it is safe and feasible to stop prostate cancer hormone therapy (androgen deprivation therapy) in certain men whose cancer has been well-controlled, potentially reducing long-term side effects like bone loss, fatigue, and sexual dysfunction. **You may be eligible if...** - You have prostate cancer that is being treated with hormone therapy (ADT) - Your PSA (a blood marker for prostate cancer) has been low and stable - You have been on hormone therapy for a specified period - You are in good general health **You may NOT be eligible if...** - Your prostate cancer has spread to distant organs (metastatic) - Your PSA levels are rising despite treatment - You have only recently started hormone therapy - You have serious other health conditions that complicate treatment decisions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALLHRH Agonist Therapy Discontinuation

The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.


Locations(2)

The University of Illinois at Chicago (UIC)

Chicago, Illinois, United States

UChicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06824818


Related Trials